Wockhardt Receives U.S. FDA Approval for Novel Antibiotic ZAYNICH™
Wockhardt Limited announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH™ (cefepime and zidebactam). This novel intravenous antibiotic is intended for the treatment of adults suffering from complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative pathogens.ZAYNICH™ is a multipenicillin-binding protein combination, pairing the fourth-generation cephalosporin cefepime with zidebactam. This combination is designed to work synergistically against the most challenging multidrug-resistant Gram-negative bacteria.Clinical Efficacy and Trial Results
The FDA approval was based, in part, on the robust...